Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES NEW PUBLICATION: HOW NCP-01 SUPPORTS BRAIN COMPUTER INTERFACES

Hemostemix Inc.'s study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. "Mitigating Challenges Facing Clinical Applications of Implantable Biosensors Supporting Brain Computer Interfaces" is co-written by Dr. Chris McNorgan, Dr. Fraser C. Henderson Sr., Dr. Ina Sarel, Dr. Ken Webb and Dr. Jeong Soo Lee.

Within the last two decades, advances in neurological medicine have led to the development of implantable electrodes for deep brain stimulation that have been used over 160,000 times since their introduction. Coupled to brain-computer interfaces, these devices restore mobility on a limited basis. The safe implantation and reliable long-term performance of implantable devices are critical to their effectiveness.

The study describes the scientific bases of how NCP-01 (NCP) leverages the patient's innate signalling processes to migrate to and engraft at the site of implantation, and trigger the factors that improve signal uptake and sensing. NCP injections over time will likely improve the performance and longevity of implants by months and years, decreasing the need for replacement electrodes.

"This is the most up-to-date review of published scientific literature on the subject of implantable biosensors and brain computer interfaces," stated Thomas Smeenk, chief executive officer. "What becomes obvious from the research is that companies like Neuralink, NeuroRestore and MindMaze will benefit from NCP's ability to home to and engraft at the site of implant, as NCP develop neurons, glial cells which support the neuron, and oligodendrocytes (which wrap myelin around the nerve) that better facilitate the implantation, acceptance, signalling capacities and longevity of electrodes. This manuscript provides the scientific bases for detailed discussions with NCP licensee-collaborators," Mr. Smeenk said.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed and patented and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors.

We seek Safe Harbor.